Uwe Platzbecker - Concepedia

Author

Uwe Platzbecker

Also Known As

Bhatt, Vijaya Raj, Björn Rüter, D C Doll, E. Gyan, E. Gökkurt, J. R. Göthert, P PLATZBECKER, Platzbecker U, Platzbecker Uwe, Platzbecker, Uwe

1.5K

Publications

37.6K

Citations

H-Index

187

Concepts

All Affiliations

University Hospital Leipzig University Hospital Carl Gustav Carus Heidelberg University Technische Universität Dresden Heinrich Heine University Düsseldorf

About

Uwe Platzbecker is an author at University Hospital Leipzig specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	128	9.9K
2	Health Sciences	26	43	3.8K
3	Engineering	5	5	132
4	Public Health	5	5	880
5	Management	1	1	28

Uwe Platzbecker

364

Publications

27K

Citations

H-Index

Page 1

	Year	Citations
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Christian Thiede, Christine Steudel, Brigitte Mohr, Blood	2002	1.7K
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia Francesco Lo‐Coco, Giuseppe Avvisati, Marco Vignetti, New England Journal of Medicine	2013	1.6K
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, NEJM Evidence Mixed-phenotype Acute LeukemiaPrognosisGenetic EpidemiologyDiagnosisPathology	2022	746
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Luca Malcovati, Eva Hellström‐Lindberg, David Bowen, Blood	2013	663
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Nature Medicine Hematological MalignancyChromatinGenome StabilityMedicineMixed-phenotype Acute Leukemia	2020	606
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group Michael Lübbert, Stefan Suciu, Liliana Baila, Journal of Clinical Oncology	2011	546
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, New England Journal of Medicine	2020	519
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Blood	2011	475
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial Uwe Platzbecker, Martin Wermke, J. Radke, Leukemia	2011	391
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial Uwe Platzbecker, Giuseppe Avvisati, Laura Cicconi, Journal of Clinical Oncology	2016	375

Page 1